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ABSTRACT 
Background: The Ethiopian ART program has improved survival of patients thru increasing 
access to ART.  Many patients fail to benefit from ART because of early drug intolerance, poor 
adherence, and potentially other reasons. Causes of variation in reported treatment outcomes 
from the ART programs in developing countries such as Ethiopia is unclear. Identification of 
the determinants of the ART outcomes could support evidence-based improvements in ART in 
Ethiopia and other resource limited settings (RLS). 
Objective: To investigate the pattern of immunologic and clinical responses and the risk 
factors for poor outcomes from ART  
Methods: This retrospective cohort study of adult patients who were started on ART between 
06/97 to 5/01 (Ethiopian Calendar) describes correlates of survival and other measures of 
response to ART. Data was retrieved from the national ART recording formats in Bella 
Defense Hospital, a major Ethiopian Military Hospital which provides free HIV care to a 
diverse population of soldiers, their dependents and retired members.  Data were collected by 
clerks and nurses as part of routine clinical documentation. Kaplan Meier analysis estimated 
the survival time probability following initiation of ART and log-rank test measured the 
significance of differences in survival times. Cox proportional hazards models used to 
determine the hazard of the outcome variables for the levels of the determinant factors of the 
outcome.  
Results: Mean follow up time was 12.5 months and median was 8 months.  Most commonly 
used ART regimens were D4T, 3TC, and NVP (45%) and  AZT, 3TC, NVP (31%). Of the 709 
patients, 18% died and 9.3% were lost to follow up, 25% transferred out and 47% remained in 
follow-up. Of the 16% who had changed their first regimen, 64% did so for side effects, 23% 
for new TB and 6% for treatment failure. During the follow up there were 61(8.6%) new TB, 
8(1.1%) new OIs, and 75(10.6%) recorded major side effects. The mean failure free survival 
time estimated for the whole cohort by Kaplan Meier analysis was 29.months.  Almost 2/3 of 
response failures (64%) occurred during the first three months after starting ART. Many 
factors (age >50, male sex, base line CD4 cell count <100, low weight, advanced WHO stages, 
and TB treatment at the start of ART) were found to be predictors of failure in bivariate Cox 
proportional hazard model. In a multivariate model, only poor/fair adherence was predictive 
(HR=5, p < 0.001), pre-treatment exposure to ARV (HR=4.2, p=0.002), side effects of ART 
(HR=2.1, p=0.002), and low functional status [bedridden] (HR=2.1, p=0.004) remained 
statistically significant (p < 0.05). Hemoglobin <10mg/dl (HR=1.7, p=0.04) was also an 
important factor when functional status was removed from the model. Poor /fair adherence 
decreased survival by 14 to 20 months than good adherence in the cohort.  
Conclusion and recommendations: As have other studies in RSL, this one found that failure 
of ART, including death, was associated with prior ART exposure, indicators of advanced HIV 
clinical stage, co-infection with TB, and poor adherence. The majority of deaths occurred 
within three months of starting ART, but reasons for this early mortality are unclear.  
Investigating reasons for early deaths, the role of drug resistance as a mechanism of ART 
failure, and strategies to enhance adherence are promising strategies for reducing ART failure. 
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I.   Introduction/Background Information 
With the advent of ARV drugs, AIDS has become a treatable chronic disease. Even in a Third 
World setting with increasing people with AIDS accessing services, a decline in death rates is 
clearly visible. In resource-limited settings patients accessing ART have a number of non-
medical needs including nutrition, shelter, transportation etc. A social system addressing these 
supports drug adherence. The public health approach, recommended by WHO for resource-poor 
settings, is an overarching principle of the Ethiopian ART program. By this approach, large 
numbers of people are facilitated to access ART and survival is maximized (1). Even though 
there are good responses for the ART, reasons for the variation in reported treatment outcomes 
from the ART programmes in developing countries, are not clearly defined (2). 
Based on various facts the time to initiate varies from one country to others and it is believed 
that the time of initiation affects the response or outcome to ART. The scientific indication for 
antiretroviral therapy is based on the clinical assessment, CD4+ T-cell count, and viral load. At 
first glance, it appears straightforward: the lower the CD4+ T-cell count and the higher the viral 
load, the higher the risk of AIDS (42, 43), and the more urgent the indication for treatment. 
Nevertheless, the best time for initiation of therapy remains the subject of controversial debate. 
The risk of AIDS must be weighed against the risks of long-term toxicity and viral resistance. 
These risks and the realization that eradication cannot be achieved at present have led to less 
rigid guidelines in many countries in recent years.  
The question now is how to practically apply the new, more appealing motto of, hit hard but 
only when necessary (44). At least all international guidelines agree that all symptomatic 
patients as well as patients with less than 200 CD4+ T-cells/µl should be treated. However, for 
patients with more than 200 CD4+ T-cells/µl, the situation becomes more confusing. Lack of 
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randomized studies forces all guidelines to rely on cohort studies, meta-analyses and evaluation 
of larger databases.  
ART in Ethiopia 
Ethiopian guidelines for Antiretroviral Therapy in adults and adolescents (1,40): the 
guidelines standardize and simplify the initiation and monitoring of ART; Standardized 
formulary for first and second-line ART, with the use of two NRTIs and an NNRTI as the 
standard first-line approach, reserving PIs for second-line is the center piece of the public health 
approach to ART. The Ethiopian National Defense Forces HIV/AIDS program also follows the 
national guidelines. 
A. When to start 
Table.1: Criteria for initiation of ART in adults and adolescents in Ethiopia, FHAPCO, 2007 
 
CD4 count not available CD4 count available
WHO clinical stage IV and III irrespective 
of Total Lymphocyte Count (TLC) 
WHO clinical stage IV, irrespective of CD4 count 
WHO Clinical stage II if TLC <1200/ mm3 WHO clinical stage III, if CD4 cell counts 
≤350/mm3 
Do not treat WHO clinical stage I, in 
absence of CD4 count 
All WHO clinical stages, if CD4 cell counts <200/ 
mm3 
TLC is only useful in deciding when to initiate ART in symptomatic patients with WHO clinical stage 
II disease. The use of CD4 cell count to guide treatment decision is advisable. For example, pulmonary 
TB may occur at any CD4 level and other conditions may be mimicked by non - HIV etiologies. 
The Ethiopian defense forces ART facilities also follow the national treatment guideline. 
 
B. ARV regimens 
First-line ARV regimens for adults and adolescents  
The preferred first-line regimen consists of NRTI backbone with one of the NNRTIs. Both 
NNRTIs are given equal preference; choice is based on patients’ conditions. ABC and TDF are 
included in this guideline to expand the choice and tailor to specific patient needs. ABC is used 
in triple NRTI regimen in rare patients with TB and pregnancy, or other situations when the 
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standard first-line regimens may not be given. Both ABC and TDF are reserved for the second-
line regimen. (ABC and TDF are only available recently since 2008).  
One of the following should be used unless there are contraindications: 
1a =ZDV3/3TC/NVP                 1c = D4T/3TC/NVP 
1b=ZDV3/3TC/ EFV                  1d =  ZDV3/3TC/NVP  
TDF/3TC/NVP or EFV selective setting 
ABC/3TC/NVP or EFV selective setting 
Second-line Regimen (during treatment failure) 
ddIa or TDF+ABC+ LPV/r b or SQV/rb or NFV or IND/r 
C. Essential steps in initiation of antiretroviral treatment and follow up of patient:  
Standardized clinical assessment of patients and, when available immunological, are mandatory 
at baseline to decide on initiation of antiretroviral therapy. Patients who do not qualify for this 
have a follow up protocol that monitors disease progression and starts antiretroviral therapy 
before life-threatening immunodeficiency sets in. Patients qualifying for antiretroviral therapy 
are thoroughly evaluated at baseline and for the rest of their lives to monitor toxicity, 
intolerance, response or failure to treatment. Before ART initiation and thereafter patient 
readiness and adherence to therapy are always assessed and necessary support provided. 
Opportunistic infections including TB, IRIS, and co morbidities are looked for and managed.  
D.  ART monitoring:  
Schedule follow up visits at monthly intervals to refill medications until week 12 of therapy, 
and then monthly for adherence counselling and medication refill with nurse 
counsellor/pharmacy personnel with every 3-month visits with clinician for clinical evaluation 
and toxicity assessment as per schedule. At each visit clinical assessment covers: 
• Symptoms/signs of potential drug toxicities 
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• Symptoms/signs of OIs 
• Adherence 
• Weight 
• Change in WHO staging  
• Laboratory Monitoring: LFT, RFT, CD4 cell count, CBC (WBC with differential, 
Haemoglobin and platelet), pregnancy test. 
E. Definitions of Treatment failure in ART 
Table.2: Definitions of treatment failure in adults and adolescents, FHAPCO, 2005 
 
 
Clinical Criteria 
  CD4 Cell Criteria 
(as determined Q 6 months) 
 
• Occurrence of new opportunistic infection or malignancy 
signifying clinical disease progression 3 months after initiation 
of ART. This is to differentiate from the immune reconstitution 
syndrome. a  
Immune reconstitution does not signify treatment failure and 
opportunistic infection should be treated as usual, without 
changes in the antiretroviral regimen. 
• Recurrence of previous opportunistic infection b  
• Onset or recurrence of WHO Stage III conditions, including 
but not restricted to:  
o HIV wasting 
o Chronic diarrhea of unknown etiology 
o Prolonged fever of unknown etiology 
o Recurrent invasive bacterial infections 
o Recurrent/persistent mucosal candidiasis  
• Return of CD4 cell to pretherapy baseline or 
below without other concomitant infection to 
explain transient CD4 cell decrease.c  
• >50% fall from therapy CD4 peak level 
without other concomitant infection to 
explain transient CD4 cell decrease.c 
 
Virologic Criteria 
• VL fails to decrease by 1 log at 6-8 weeks, 
OR 
• Does not remain < 400 copies/ml after 24 
weeks 
a Immune reconstitution syndrome (IRS) is characterized by the appearance of signs and symptoms of an 
opportunistic disease a few weeks after the start of potent antiretroviral therapy in the setting of advanced 
immunodeficiency, as an inflammatory response to previously subclinical opportunistic infection. It is also 
possible that this immunological reconstitution may lead to the development of atypical presentations of some 
opportunistic infections.  
b Recurrence of TB may not represent HIV disease progression, as reinfection may occur. Clinical evaluation is 
necessary.  
c If patient is asymptomatic and treatment failure is being defined by CD4 cell criteria alone, consideration should 
be given to performing a repeat CD4 cell count if resources permit.  
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Table.3: Definitions of treatment failure in adults and adolescents, FHAPCO, 2007 
 
 Definition 
Clinical Failure a New or recurrent WHO stage 4 condition b c 
Immunologic Failure d • Fall of CD4 count to pre-therapy baseline (or below); 
• 50% fall from the on-treatment peak value (if known); 
• Persistent CD4 levels below 100 cells/MM3 
Virological Failure Plasma viral load above 10,000 copies/ml in duplicates after six months on 
ART. 
a Should be differentiated from Immune Reconstitution Inflammatory Syndrome (IRIS). 
b Certain WHO clinical conditions (e.g. pulmonary TB, severe bacterial infections), may indicate treatment failure and should 
be investigated. 
c Some WHO clinical stage 4 conditions (lymph node TB, uncomplicated TB pleural disease, esophageal candidiasis, recurrent 
bacterial pneumonia) may not be indicators of treatment failure and thus do not require consideration of second-line therapy. 
 d Without concomitant infection to cause transient CD4 cell decrease. If patient is asymptomatic and treatment failure is being 
defined by decreased CD4 cell criteria alone, consideration should be given to performing a repeat CD4 cell count before 
establishing diagnosis of treatment failure. 
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II. Literature review 
Response to ART  
Patients due to various factors show different response to ART. Patients may show virologic, 
immunologic, or clinical response. Of these, the earliest indicator is virological success or 
failure (decrease or increase in viral load). This is followed, often a little later, by 
immunological treatment success or failure (rise or fall in CD4+ T-cell count). Clinical 
treatment failure, if it occurs, usually only becomes apparent much later. First the lab values 
deteriorate, then the patient. On the other hand, success of treatment may be seen much earlier; 
many patients suffering from constitutional symptoms rapidly improve on HAART (3,4, 5). 
A. Virological response 
Virological treatment success is usually understood as being the reduction of viral load to below 
the level of detection of 50 copies/ml. This is based on the understanding that, the more rapid 
and greater the decrease in viral load, the longer the therapeutic effect (6, 7, 8). On HAART, 
viral load declines in two phases. An initial, very rapid decrease in the first few weeks is 
followed by a slower phase, in which plasma viremia declines only slowly. Virologic failure is 
when viral load above the level of detection after six months of treatment or if a rebound in 
viral load is confirmed (9). Numerous studies indicate that replication and therefore 
development of resistance can continue even with an undetectable virus load. The good news is 
that morbidity and mortality may be lowered significantly even if the viral load is not decreased 
below the level of detection (4, 10, 11). A large cohort study has shown that CD4+ T-cells do 
not drop as long as the viral load remains below 10,000 copies/ml (12). The most important risk 
factors for virological treatment failure are extensive pre-treatment with antiretroviral drugs 
(pre-existing resistance mutations) and non-adherence (11,13,14,15). 
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B. Immunological response 
Immunological treatment success is generally defined as an increase in the CD4+ Tcell count. 
A more precise definition for immunological treatment success does not currently exist. 
Depending on the study, increases by 50, 100 or 200 CD4+ Tcells/µl or increases to above 200 
or 500 CD4+ T-cells/µl are defined as success. Failure is usually described as the absence of an 
increase or as a decrease in the CD4+ T-cell count in patients receiving HAART. It is difficult 
to individually predict the immunological success of therapy for patients on HAART, as it 
varies significantly from one person to another. As with the decrease in viral load, the increase 
in CD4+ T-cell count also occurs in two phases. After a first, usually rapid increase over the 
first three to four months, further increases are considerably less pronounced. In a prospective 
study involving some 1,000 patients, the CD4+ T-cell count increased during the first three 
months by a median of 21.2 CD4+ T-cells/µl per month; in the following months the increase 
was only 5.5 CD4+ T-cells/µl (15). It is still under debate whether the immune system is 
restored continuously after a long period of viral load suppression or whether a plateau is 
possibly reached after three to four years, beyond which there is no further improvement (16, 
17, 18). The lower the CD4+ T-cell count at baseline, the less likely it is to normalize 
completely (19, 20, 21). In the Swiss Cohort, only 39 % of 2,235 patients who had begun 
HAART in 1996-97 reached a CD4+ T-cell count above 500/µl (21). However, it appears that 
the introduction of therapy within the first 3-6 months provides certain clues as to how well the 
immune system will be restored (20). Immunological treatment success is not necessarily linked 
to maximal viral suppression; even partial suppression can result in improved CD4+ T-cell 
count (3, 10, 22). The initial level of viral load is also not significant; what seems to be decisive 
is that the viral load remains lower than before treatment (3, 23). Significant drops in CD4+ T-
cell count were observed in patients with a suppressed viremia who switched to a simplified 
 8
regimen of ddI and tenofovir plus nevirapine (24). The reason for this seems to be related to 
negative interactions between ddI and tenofovir. In another study, the CD4 increase on 
abacavir+3TC was significantly better than on AZT+3TC (both combined with efavirenz), 
despite comparable virological success. This may be related to the myelotoxicity of AZT (25). 
Once CD4+ T-cells have normalized and plasma viremia remains undetectable, it is unlikely 
that they will reduce significantly (26).  
C. Clinical response 
Clinical treatment success is dependent on virological and immunological therapeutic success. 
In individual patients, clinical response is not always easy to assess. Clinical success is almost 
always evaluated via clinical endpoints (AIDS-defining illnesses, death), although the 
improvement on HAART in a patient with considerable constitutional symptoms should also be 
seen as clinical success. With regard to risk of disease progression, the immunological response 
is at least as important as the virological response (3, 27, 28).  
Clinical failure is usually defined as the development of an AIDS-associated condition or even 
death. However, illness is not always indicative of clinical treatment failure. This is particularly 
true for the immune reconstitution inflammatory syndrome (IRIS), where a pre-existing, 
subclinical infection becomes apparent during the first weeks following initiation of 
antiretroviral therapy. On the other hand, if a patient develops serious side effects or even dies, 
this should clearly be regarded as treatment failure. Many severe, life-threatening events that 
affect HIV infected patients on HAART today are associated neither with HAART nor AIDS 
(29). 
In many areas, the incidence of AIDS has been reduced to less than a tenth (30). In patients who 
are continuously followed in specialized centers, AIDS has become a rare occurrence. The 
mortality rate has continued to decline over time (31). In the Euro- SIDA Cohort, the risk of 
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suffering or dying from AIDS in the years 1998-2002 was half that of 1996-1997 (32). The 
Swiss cohort also showed that the effect of HAART increases over time after more than two 
years on HAART, the risk of disease progression was only 4 % of the risk without HAART 
(34,35,36). In the SV14604 Study involving 3,485 patients, the frequency of AIDS and death 
was reduced by about 50 % in the group receiving AZT+ddC+saquinavir hard gel, compared to 
the groups on dual therapy (37). 
According to a more recent investigation, the effect on the individual AIDS diseases appears to 
be different: the most obvious is the decline in the incidence of viral OIs, although this is not so 
pronounced for fungal infections (38).  
D. Lost to follow Up/drop/discontinued 
Due to different reasons significant number of patients lost to follow up or discontinued their 
treatment. This numbers are especially high in developing countries. Reports from Ethiopia 
have indicated that about 20% of those started on ART lost to follow UP. Since January 2005, 
97,258 people put on ART as of end of June, 2007. Of the total patients who have started ART 
72, 884 of them are currently alive and on treatment.  Around 24,374 people are not currently 
following their drugs. As the regional data indicates 12,685 (13.1%) people were defaulted or 
lost/drop from treatment, 5731(5.9%) deaths were reported so far and 140 people stopped 
treatment in consultation with physicians. However, the status of 6100 people is not known.  
The highest drop out rate were recorded in five major regions where 90% of patients getting the 
services - Addis Ababa (40%), Amhara (22%), Oromia (15%), SNNPR (7%) and Tigray (8%). 
In Ethiopian National Deference Forces, as of September 2008, about 5692 patients started on 
ART, of this only 3279 are currently on ART. The others are (116) lost, (215) drop and (142) 
dead (39). 
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When to start ART 
The regenerative capacity of the immune system in older patients is significantly reduced (45, 
46), this has not been acknowledged in any guidelines to date. More importantly, the risk of 
developing opportunistic infections also depends on age (47).  The CASCADE Study (47) 
exemplifies this: a 25 year-old patient with 100 CD4+ T-cells/µl and a viral load of 100,000 
copies/ml has a risk of approximately 10 % for developing AIDS within six months. For a 55 
year-old, this level of risk is reached at 150 CD4+ T-cells/µl and a viral load of 30,000 
copies/ml. It is also important that not only the absolute CD4+ T-cell count is considered, but 
the percentage value too. In particular, when the CD4 count is high and the immune status 
appears good, the CD4 percentage is the most important parameter for predicting the risk of 
developing AIDS. In one study, the risk of progression for patients with more than 350 CD4+ 
T-cells/µl was increased approximately four fold, if the percentage of CD4+ T-cells was below 
17 % (48).  
Determinant factors of response to ART 
Various studies have identified different determining factors of response to ART which are 
related to the base line values, the type and regimen of ARV drug, adherence, the patient socio-
economic and demographic factors, other concomitant disease and related conditions. 
A. Base line characteristics or Values (CD4 T-cell count, immune status, pre-ART 
exposure to ARVs, Clinical condition or stage and others) 
Large cohorts repeatedly attempt to prove that the starting time point influences virological or 
immunological treatment success. Factors like base line CD4 cell count, pre –ART exposure to 
ARV, immunologic status and compliance are associated with the responses.  
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Many cohort studies have clearly demonstrated that virological response is poorer if the CD4+ 
T-cell count at initiation of treatment was low and the viral load high (15,55,56,57). It is usually 
said that the higher the viral load and the lower the CD4+ Tcell count, the less the virological 
success of HAART. However, in contrary to defenders of an early initiation of HAART, two 
large cohorts in which only treatment naïve patients were studied doesn’t support it (14,62). In 
the French APROCO Cohort, in which greater differentiation existed between treatment-naïve 
and treatment-experienced patients (63), treatment-naïve patients with a high viral load at 
baseline showed at most an insignificant negative trend. That viral load and CD4+ T-cell count 
have predictive values in all cohort studies in which most (up to 91 %) patients included were 
usually pre-treated with NRTIs, indicates one thing above all: virological success of HAART 
may be compromised in patients with prolonged mono or dual therapy. Previous nucleoside 
analog therapy has been a risk factor for virological treatment failure in many cohorts (15, 55, 
59, 60). In the HOPS Cohort, lack of prior therapy was decisive particularly for long-term 
treatment success (64). This is particularly important in PMTCT served women’s. Other factors 
for the relative risk of virological failure were increased in patients with substantial 
immunosuppression (below 50 CD4+ T-cells/µl) or very high viral load and compliance. 
Adherence was an important and even decisive predictor in the few studies in which it has been 
investigated (15, 65, 66). If these aspects are considered, the issue of whether virological 
response is really poorer with less favorable baseline values becomes less clear-cut. Even a 
patient with high viral load and a very low CD4+ T-cell count can potentially control infection 
quite successfully (67). 
Immunological response: Multiple factors influence the increase in CD4+ T-cells: duration of 
immunosuppression, age, thymus size or extent of thymus degeneration (63). Studies showed 
that the rise in CD4+ T-cells is similar, although levels remained lower if the CD4 count was 
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initially low. Furthermore, in some experience immune reconstitution is rarely complete if 
values were low initially; the more damaged the immune system, the less likely a complete 
recovery in the long run (68). In the Swiss Cohort, having a low CD4+ Tcell count at baseline 
was a clear risk factor for not attaining 500 CD4+ T-cells/µl after four years (20, 69). 
Numerous studies suggest that qualitative immune reconstitution does not initially occur at the 
same pace as quantitative reconstitution ((70,71,72, 73).  
Most studies have found a clear correlation between CD4+ T-cell count at initiation of HAART 
and rates of both AIDS and death (10, 13, 49, 74).  Above all, if the CD4+ T-cell count is below 
50/µl when starting therapy, the risk for developing AIDS remains permanently high (65). In 
other cohorts, the risk remained elevated even below a CD4+ T-cell count of 200/µl (74, 75). 
The CD4+ T-cell count at the start of treatment correlated highly with the probability later in 
the course of the illness of AIDS or death (49). Viral load at baseline was only relevant if it was 
at a very high level, i.e. above 100,000 copies/ml (67). 
Studies on the base line value also identified significance association among advanced disease 
stage, lower baseline CD4 T cell count and longer duration of HIV infection with poor 
immunologic and clinical responses (49, 76). 
A retrospective chart review of 235 HIV-infected Native Americans receiving services at an 
urban medical center, providing 782.7 person-years of follow-up, to identify determinants of 
survival reviled that the use of HAART therapy and CD4 count was the strongest predictor of 
survival from time of AIDS diagnosis. The main outcome measures were time from study entry 
and from incident AIDS diagnosis to death. Death rates fell from 18.4 (13.3–25.4) per 100 
person-years to 6.4 (4.6–8.8) per 100 person-years (RR 0.35, p _ 0.0001). Factors associated 
with the greatest reduction in risk of death from time of study entry were current use of 
HAART, HR 0.13 (0.06–0.30, p _0.001), and CD4 count _200 at entry, HR 0.16 (0.08–0.35, p 
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_ 0.001). Earlier diagnosis and access to effective medical treatment will be key factors in 
reducing disparities in health brought about by HIV infection in Native American/Alaska 
Native communities (77).  
Other  Study of Characteristics, determinants, and clinical relevance of CD4 T cell recovery to 
<500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy, 
that is  longitudinal CD4 T cell count was analyzed in 293 participants of the Swiss HIV Cohort 
Study who had had a plasma HIV-1 RNA load <1000 copies/mL for > or =5 years. 
Determinants of incomplete responses and clinical events were evaluated using logistic 
regression and survival analyses. The results showed: the median CD4 T cell count increased 
from 180 cells/microL at baseline to 576 cells/microL 5 years after ART initiation. A total of 
35.8% of patients were incomplete responders, of whom 47.6% reached a CD4 T cell plateau 
<500 cells/microL. Centers for Disease Control and Prevention HIV-1 disease category B 
and/or C events occurred in 21% of incomplete responders and in 14.4% of complete 
responders (P>.05). Older age (adjusted odds ratio [aOR], 1.71 per 10-year increase; 95% 
confidence interval [CI], 1.21-2.43), lower baseline CD4 T cell count (aOR, 0.37 per 100-cell 
increase; 95% CI, 0.28-0.49), and longer duration of HIV infection (aOR, 2.39 per 10-year 
increase; 95% CI, 1.19-4.81) were significantly associated with a CD4 T cell count <500 
cells/microL at 5 years. The median increases in CD4 T cell count after 3-6 months of ART 
were smaller in incomplete responders (P<.001) and predicted, in conjunction with baseline 
CD4 T cell count and age, incomplete response with 80% sensitivity and 72% specificity. 
Individuals with incomplete CD4 T cell recovery to <500 cells/microL had more advanced 
HIV-1 infection at baseline. CD4 T cell changes during the first 3-6 months of ART already 
reflect the capacity of the immune system to replenish depleted CD4 T lymphocytes (20).  
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Analysis of prospective studies also reviled CD4 base line and at 6 months and plasma viral 
load of >100,000 copies/ml after 6 months of treatment, cell count has been considered one of 
the most important variables for predicting response to antiretroviral treatment: The lower the 
count before treatment is started, the higher the risk that treatment will fail. European 
researchers now suggest that the CD4 cell count at 6 months into treatment is a substantially 
more powerful prognosticator than is the nadir count. More than 9000 HIV-infected patients at 
all stages of disease were monitored after beginning their first course of combination 
antiretroviral drugs. Patients were followed for at least 6 months (13,408 person-years of 
follow-up) in 13 separate European and North American cohorts. Nadir count was associated 
strongly with progression to AIDS or death in a crude analysis, but it was no longer an 
independent predictor when 6-month CD4 cell count was included in the analysis. Prognosis 
was poorest for patients with 6-month CD4 cell counts of <25/mm3. These findings provide 
statistical backing for the frequent clinical observation that patients who show brisk rises in 
CD4 cell count after beginning antiretroviral therapy tend to do better than do those with 
sluggish responses, even if nadir CD4 cell counts are similar. This evidence should give 
patients an additional impetus to adhere to their drug regimens early in treatment (78). 
B. ARV type, ART regimen and adherence 
Nucleoside-only regimens and poor adherence are known to associate with treatment failure. 
Retrospective analysis was conducted of HIV-infected patients followed in an urban HIV clinic 
with an HIV RNA measurement ≤400 copies/mL on ART between January 1, 2003, and 
December 31, 2004. The primary endpoint was treatment failure, defined as virologic failure 
(≥1HIV RNA measurement >400 copies/mL), unsanctioned stopping of ART, or loss to 
follow-up. Prior ART adherence and other baseline patient characteristics were determined at 
the time of the first suppressed HIV RNA load. Predictors of failure were assessed using 
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proportional hazards modeling. The results were, of 829 patients in the clinic, 614 had at least 1 
HIV RNA measurement ≤400 copies/mL during the study period. Of these, 167 (27.2%) 
experienced treatment failure. Baseline characteristics associated with treatment failure in the 
multivariate model were: poor adherence (hazard ratio [HR]= 3.44; 95% confidence interval 
[CI]: 2.34 to 5.05), absolute neutrophil count <1000/mm3 (HR =2.90, 95% CI: 1.26 to 6.69),  
CD4 count <200 cells/mm3 (HR= 1.90, 95% CI: 1.31 to 2.76), nucleoside-only regimen (HR = 
1.75, 95% CI: 1.08 to 2.82), prior virologic failure (HR = 1.70, 95% CI: 1.22 to 2.39) and ≥1 
missed visit in the prior year (HR = 1.56,95% CI: 1.13 to 2.16). More than one quarter of 
patients in a heterogeneous clinic population had treatment failure over a 2-year period. Prior 
ART adherence and other data readily identify patient characteristics that could trigger specific 
interventions to improve ART outcomes (79). 
C. Patient socio-economic and demographic factors and adherence 
Studies have shown that patients characteristics and related conditions like older age, Female, 
poor socio-economic status, and injection drug use are associated with poor treatment response.  
On the Swiss HIV Cohort study older age (adjusted odds ratio [aOR], 1.71 per 10-year increase; 
95% confidence interval [CI], 1.21-2.43), and longer duration of HIV infection (aOR, 2.39 per 
10-year increase; 95% CI, 1.19-4.81) were significantly associated with a CD4 T cell count 
<500 cells/microL at 5 years and with other factors predicted incomplete responses (20). 
AGE 
The risks of developing AIDS within six months, as identified in 3,326 patients from the pre-
HAART era, depends on deferent factors. The range of individual risk of progression varies 
widely from 0 to almost 50 %. For a 55 year-old patient with a CD4+ T-cell count of 50/µl and 
a viral load of 300,000 copies/ml, the risk of progressing to AIDS within the next 6 months was 
44.8 %. In a 25 year-old patient with 500 CD4+ Tcells/µl and a viral load of 3,000 copies/ml, 
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the risk was only 0.3 %. This demonstrates the importance of these parameters for estimating 
the individual risk and indication for treatment. However, the age of the patients, which 
according to these data significantly increases the risk of progression, has so far not been 
included in any of the guidelines (48,67). 
D. Concomitant disease conditions, factors that affect drug pharmacodinamics and 
kinetics and related factors 
The above mentioned analysis of prospective studies, other independent risks for poor outcome 
(defined as new AIDS-related events or death) were age older than 50, HIV acquired through 
injection drug use, AIDS-related infection or malignancy diagnosed before or in the first 6 
months of treatment and plasma viral load of >100,000 copies/mL after 6 months of treatment  
Review from Haiti also identifies coinfection with tropical diseases and tuberculosis, along 
with malnutrition and limited laboratory monitoring of therapy as important determinant factor 
for response to ART. The one-year survival rate of adults and children with the acquired 
immunodeficiency syndrome (AIDS), without antiretroviral therapy, has been about 30 percent 
in Haiti. High rates of coinfection with tropical diseases and tuberculosis, along with 
malnutrition and limited laboratory monitoring of therapy, may decrease the efficacy of 
antiretroviral therapy in these countries.  Study on the efficacy of antiretroviral therapy in 
patients with AIDS and without previous antiretroviral therapy who were treated beginning in 
March 2003 in Port-au-Prince, Haiti showed: during a 14-month period, three-drug 
antiretroviral therapy was initiated in 1004 patients, including 94 children under 13 years of age. 
At enrolment, the median CD4 T-cell count in adults and adolescents was 131/ mm3 
(interquartile range, 55 to 211/ mm3); in children, a median of 13 percent of T cells were CD4-
positive (interquartile range, 8 to 20 percent). According to a Kaplan–Meier survival analysis, 
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87 percent of adults and adolescents and 98 percent of children were alive one year after 
beginning treatment. In a subgroup of 100 adult and adolescent patients who were followed for 
48 to 56 weeks, 76 patients had fewer than 400 copies of human immunodeficiency virus RNA 
per milliliter. In adults and adolescents, the median increase in the CD4 T-cell count from 
baseline to 12 months was 163/ mm3 (interquartile range, 77 to 251/ mm3). In children, the 
median percentage of CD4 T cells rose from 13 percent at baseline to 26 percent (inter quartile 
range, 22 to 36 percent) at 12 months. Treatment-limiting toxic effects occurred in 102 of the 
910 adults and adolescents (11 percent) and 5 of the 94 children (5 percent)(80). 
A review by Christian Hoffmann and Fiona Mulcahy (81, 82) on discordant response also 
reviled age, base line CD4 cell count, type of regimen and concomitant infections as important 
factors. Failure to achieve every one of the therapeutic goals; clinical, immunological and 
virological is referred to as a discordant response. Some patients may have virological treatment 
success without immunological improvement, continuing to have a very low CD4+ T-cell count 
despite undetectable viral load (5, 70, 71). In addition to age, the risk factors for a lack of 
immunological treatment response, despite good viral suppression, include low CD4+ T-cell 
counts at baseline, as well as having a low viral load at the start of treatment (20, 83). In older 
patients, immunological response is often only moderate in comparison to virological response. 
Various studies have demonstrated that the probability of not achieving a rise in CD4+ T-cell 
count increases with patient age and with progressive decrease in thymus size as detected by 
CT (5, 84). Patients who are intravenous drug users also have relatively poor increases in CD4+ 
T-cells compared to other patients (84).Other possible causes for a lack of immunological 
response despite good viral suppression may be immuno- or myelosuppressive concomitant 
therapies. Conversely, HAART may be extremely effective immunologically and induce 
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significant increases in the CD4+ T-cell count, while viral load remains detectable. This can 
sometimes be observed in children and adolescents (67).  
Study from Ethiopia 
A study at typical Ethiopian district hospital (Arbaminich), found that HAART decreased death 
and tuberculosis incidence rates in HIV infected Ethiopian patients. Mortality declined by 65% 
and tuberculosis incidence rate was reduced by almost 90%. Most of the deaths in the HAART 
cohort occurred within the first three months of therapy. Few patients experienced life-
threatening drug side effects. However, both the mortality and the tuberculosis incidence rates 
are higher in this cohort than in cohorts from the developed world and unfortunately, many of 
the patients had advanced disease at time of diagnosis. A study using virologic and 
immunological end points found that HAART was equally effective in African patients and 
challenged an earlier report that virological failure was more common in Africans while 
improved survival is encouraging news, it is lower than in the developed world (85). 
Although the survival of HIV infected patients has improved following the introduction of 
HAART, patients in resource-poor countries have higher mortality rates especially during the 
first weeks of treatment. In the study that examined factors predicting mortality in Ethiopian 
patients treated with HAART, base line WHO stage, BMI and TLC strongly associated. Out of 
162 recruited, 152 treatment-naïve patients contributed 144 person-years of observation (PYO). 
86 (57%) of them were men and their median age was 32 years. The overall mortality rate was 
16.7 per 100 PYO (24 deaths/144.1 PYO). The highest death rate occurred in the first month of 
treatment. Compared to the first month, mortality declined by 9-fold after the 18th week of 
follow-up. Being in WHO clinical stage IV and having TLC<=750/mcL were independent 
predictors of death. BMI <=18.5 kg/m2 at baseline was associated with death in univariate 
analysis.   Weight loss was seen in about a third of patients who survived up to the fourth week, 
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and it was associated with increased death. Decline in TLC, HGB and BMI was associated with 
death in univariate analysis (86).                                                                                              
Unpublished Quality assessment study on the three defense hospitals namely AFTGH, Bella 
and Debrezeit Air force hospitals reviles  that  significant change was seen at CD4 count and 
weight of clients after initiation of ART at six months( p<0.001). The mean CD4 cells/mm3 
before and after ART was 105.6 and 234.5 (SD ±70.6 and 120.7) respectively, and the median 
CD4 count before initiation of ART was 93cells/mm3, while after treatment at six months 
increased to 219 cells/mm3 . The 50 %of clients before ART weigh between 61(the 75 
percentile) and 49(the 25 percentile), while after ART weigh between 66(the 75 percentile) and 
55, the 25 percentile (87).  
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Figure.1: Conceptual framework of determinant factors of response to ART 
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III. Rationale/relevance of the study 
Patients respond to ART differently and their outcomes are affected by various factors. We also 
observed variation on the response of patients for ART in the health facilities. Various studies 
have identified many determinants of response to ART, some studies are inconclusive, and 
most studies have been conducted in developed countries. In Ethiopia even though the ART 
program lasts for about 5 years, only few evaluations of outcome and none at Ethiopian defence 
forces have been completed. The Ethiopian treatment guidelines have not been supported by 
endogenous studies. Further more, to date there is no study conducted to evaluate the outcome 
of ART and the determinants for the response in the Ethiopian military.   
Identification of the specific determinant factors and evaluation of the outcomes of ART 
provide help to have full insight on the achievements and challenges of ART program and 
develop evidence based public health approach of ART. Therefore, this study will support 
treatment protocols and also helps to see the achievements of the ART program so far in 
Ethiopian military. 
The final outcome of the study also contributes to the country in general and to the national 
Defence forces health system in particular, to the revision of treatment guidelines, the clinical 
practice and health system administration and the development of an effective and efficient 
strategy for better outcome of ART.      
It also examines programme factors like adherence, time of initiation of ART, pre-treatment 
ARV exposure and demographic factors. The results of the evaluation provide the health 
management system of the Health Department of the National Defence Forces of Ethiopia 
relevant information on the relationship of key ART programme factor to ART outcome. The 
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study evaluates the effects of current practice and use as baseline/the background information 
for further prospective studies. 
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IV. Objectives of the Study 
The general objective was to examine the response of HIV patients to the ART and identify the 
determinant factors for the response in the Ethiopian military ART facility.  
Specific objectives 
   The study focused in the following specific objectives: 
• To describe the patterns of response to ART in HIV patient. 
• To evaluate the impacts of ART on the patients survival and immunologic and 
clinical outcome 
• To estimate the time to failure of ART 
• To identify the determinants for response to and failure of ART 
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V.   Methodology 
Study Design: Historical cohort study of HIV patients who started ART at HIV/AIDS clinic 
of Bella Defense Hospital, one of the referral hospitals for Ethiopian military health facilities.  
Study Area and time: The study was conducted in Bella Defense Hospital, the Ethiopian 
military hospitals, which is located in Addis Ababa and is used as main referral hospital and the 
teaching center for the Defense forces, civil servants in the Defense institutions, their families 
and dependents. The ART clinic serves a diverse patient population from the defense forces, 
their dependents and retired army. Patients were managed by physicians, health officers, nurse 
practitioners, the latter two under the supervision or consultation of ART physicians, or by 
attending physicians alone. Standardized paper charts (National ART recording formats) were 
used to store records and laboratory results. The records contained information on patient 
demographics, laboratory, HIV risk behaviors, adherence to ART, medications, and diagnoses, 
which were entered by data clerks/ ART nurses as part of routine clinical documentation. 
Laboratory results and appointments were regularly recorded according to the national 
guideline.  Bella Defense ART clinic was supported by University of California San Diego- 
Ethiopia (UCSD-E). The study covered ART patients who started ART treatment from 
05/06/1997E.C to 22/05/2001E.C.  
Source Population: The source population for this study was all ART patients of the 
Defense forces and their family members, civil servants in the Defense forces and their family 
members. 
Study Population: patient started on ART at Bella Defense Hospital and fulfilled the 
inclusion criteria of the study.  
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Inclusion Criteria 
• On  ART regimen that includes at least 3 drugs  
• Presence of pre-treatment CD4 cell count.  
• CD4 cell count obtained with in the treatment period based on the national 
guideline.  
• Laboratory and clinical data available  
• Age 18 years and above.  
• Patients started ART at the facility 
Exclusion Criteria 
• With no enough/relevant laboratory and clinical data. 
• Those patients who started ART at other ART sites. 
 
Sample size: All ART patients were taken and about 709 adult ART patients who fulfilled 
the study criteria included. There were about 750 HIV patients on ART during the study period 
but some of them didn’t have adequate data and didn’t fulfill the study criteria. Patients who 
enrolled in the cohort had the following data collected: current age, age at time of ART 
initiation, gender, education level, literacy, substance use, and ART adherence data, original 
and current ART regimen, and duration of current ART regimen, CD4 count base line and 
follow up, disease stage at entry, opportunistic infections, and other co-morbidities. Death and 
other important events and occurrence of treatment failure were also documented. How ever 
there were some irregularities or lack of consistency in documentations. 
Sampling Procedure/Scheme: (Figure-3) 
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Figuer.3: Sampling scheme and study follow, Bella Defence Hospital, 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study population 
N=752, those started ART at Bella Defence H, ART 
clinic, 05/06/1997E.C to 22/05/2001E.C.  
N=384, didn’t start 
ART 
N=335, on follow up/on treatment 
Source of study population 
N=1136, All HIV patients in Bella Defence H, 
ART clinic, 05/06/1997E.C to 22/05/2001E.C.  
Sample Size: N=709, individuals who fulfilled 
the inclusion and exclusion criteria 
Exclusion Criteria: Age<18 years, no enough/relevant 
laboratory and clinical data, those patients started ART at 
other ART sites and transferred in (N=43). 
Inclusion Criteria: On ART regimen that includes at least 3 
drugs, any pre-treatment CD4 cell count, CD4 cell count 
obtained with in the treatment period based on the national 
guideline, laboratory and clinical data available since the 
initiation of ART therapy, Age 18 years and above, Pts 
started ART at AFTGH. 
Dead, N=129 
Lost to follow up, N=66,  
Transfer out to other facility, 
N=179 
 27
VI. Data Collection and Measurement 
VI.I. Expected outcome  
The study was conducted based on the assumptions of the following dependent and independent 
variables 
The Dependent and Independent Variables 
Dependent variables: 
• Immunological response – CD4 count (change in the CD4 count over time and failure). 
• Clinical response – survival, death, development of OIs or AIDS defining illness. 
• Change in therapy – use of 2nd line treatment regimen. 
• Weight –change in weight over time 
Independent variables: 
• Adherence 
• Type of regimen 
• ARV side effects 
• Previous exposure to ARVs 
• Base line – CD4, Weight, Hemoglobin, Clinical stage and other patient characteristics. 
• Time at HIV diagnosis 
• Concomitant infections/situation, immunemodulatory drugs 
• Socio-demographic characteristics – Age, Sex, Socio economic characteristics.  
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Operational definition 
• Response failure was occurrence of any of the three outcome immunologic failure, clinical 
failure, and change to 2nd line drugs. 
• Death was any death occurring during ART regardless of the  cause excluding accidents 
and other unrelated. 
• Success and failure were according to the national ART guideline definition and criteria 
(see Introduction) 
• Adherence rated according to the national guideline as 
follows
 
VI.II. Data Collectors and their Training  
UCSD-E ART data clerks and site data coordinator who were  working on filling the ART 
registers and formats and already had the  experience on ART data recording were utilized for 
this  research. And also additional 5 experienced nurses trained and oriented on the data entry 
and the research questionnaires/formats. 
VI.III. Data Collection 
Data was collected from each subject using the standard Ethiopian national ART recording 
formats. For this study secondary data from the national ART registers was collected using the 
developed questioners. Data management, quality assurance and training were being provided 
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by the UCSD-E M&E team. The clinical data merged with laboratory data.  Clinical data 
elements included: age, sex, pre-treatment CD4 count and serial CD4 count information, 
treatment regimen, history of treatment related toxicity, adherence (based on ART clinic and 
pharmacy records) and HIV disease stage. 
VII. Data Management, Analysis, Quality Assurance and 
Interpretation  
Data Coding: - All socio-demographic variables categorized. Numbers identifying variables 
and appropriate variable name was given. The layout scheme was developed and the codes for 
each variable identified. Data was entered into and processed using SPSS Version 15. . 
Data Entry:  Data entry from the questioner was done by the principal investigator. Counter 
check done at each step. 
Data Cleaning: Data were carefully checked for errors before they were analyzed.  Frequency 
tables done and checked for possible outliners and wrong values.. Logical and consistency 
errors were also checked after completing data entry.  
Quality Assurance: there were direct supervision of data personnel on the data collection and 
cleaning done by the researcher.  
Data Analysis  
Data was analysed using SPSS, version 15. Frequencies, proportions and summary statistics 
were used to describe the study population in relation to relevant variables. Socio-demographic 
subgroups were compared with population characteristics where possible. Therefore, 
descriptive data listing of demographic and laboratory characteristics was done 
meticulously.  An attempt was made to determine characteristics of patients with end points by 
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comparing the characteristics of those with and with out response failure. General linear model 
used for the evaluation of change in the repeated measurement. 
Cox proportional hazard model was used to determine the risk of the outcome variables for the 
determinant factors of the outcome. Kaplan Meier survival analysis    to estimate the survival 
time probability following initiation of ART with and with out determinant variable and Log 
rank test for comparing survival curves were utilized.  
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VIII. Ethical Considerations 
Ethical clearance for this study was obtained from the ACIPH –Gonder University IRB. 
Permissions also obtained from Bella Defense Hospital administration.  
The study didn’t identify individuals or linked to specific groups. Anonymity of the study 
participants was maintained by omitting names and minimizing other identifying information. 
Confidentiality of the data also be maintained and only used for this study. Appropriate ethical 
conduct was maintained throughout the study process and then after during reporting and 
presentation. 
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IX. Results 
A total of 750 patient records who started ART from 05/06/1997E.C to 22/05/2001E.C were 
reviewed and 709(94.5%) fulfilled the inclusion criteria and had adequate information and 
included in the study. 
6.1. Socio –Demographic characteristics 
Among the participants, 431(60.7%0) were male and 273(38.5%) female. The minimum age 
was 20, while the maximum was 60. Nearly 75%of the participants were between the age group 
20 to 39 and the remaining 40 and above. The mean and median age are 34 (SD=7.629) and 33 
respectively. 
Majority of the participants were orthodox Christian 581(81.8%) by their religion, married 
461(64.9%) and secondary education level 319(44.4%). One hundred sixty one (22.7%) were 
active military and 233(33.7%) were employed (most of them at NDFE), while 207(30%) were 
unemployed. Significant number of the participants leaves outside Addis Ababa 310(43.7) at 
the start ART. 
Other social characteristics like disclosure status, 381(53.7) disclosed their HIV status at the 
start of ART and 167(23.5) had some sort of addiction to tobacco, alcohol, chat or other. 
Twenty three (8.3% of female) were pregnant at the start or become pregnant during the 
treatment (Table -4). 
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Table. 4. Distribution of participants (ART patients) by socio-demographic 
characteristics, Bella Defence Hospital, 2009. (N=709) 
 
Socio demographic characteristics 
 
Frequency in 
number 
 
% 
Sex(N=704) 
Male 
Female  
 
431 
273 
 
60.7 
38.5 
Age(N=707) 
20 - 29 
30 – 39 
40 – 49 
50 + 
 
218 
321 
142 
26 
 
30.7 
45.2 
20 
3.7 
Marital status(N=701) 
Never married 
Married 
Separated 
Divorced 
Widow/widowed 
 
137 
461 
23 
35 
43 
 
19.3 
64.9 
3.5 
4.9 
6.1 
Occupation(N=690) 
 Military  
Employed     
Unemployed     
 Other 
 
161 
233 
207 
89 
 
22.7 
33.7 
30 
12.9 
Level of education(N=675) 
No education 
Primary 
Secondary 
Tertiary  
 
42 
263 
315 
65 
 
5.9 
37 
44.4 
7.7 
Religion(N=679) 
Orthodox 
 Muslim 
Protestant 
Catholic 
Other  
 
581 
45 
46 
3 
4 
 
81.8 
6.3 
6.5 
0.4 
0.6 
Place of residence(697)    
Addis Ababa and surrounding 
Outside Addis Ababa     
 
387 
310 
 
54.5 
43.7 
Disclosure status(N=697) 
             Yes 
             No 
 
381 
315 
 
53.7 
44.4 
Addiction History (Tobacco, alcohol, 
chat…)(N=683) 
        Yes 
         No 
 
167 
516 
 
23.5 
72.7 
 
6.2. Baseline characteristics of the study participant 
Most of the participants had baseline CD4 cell count 50 and below 211(29.7%) and only 59 
patients (8.3%) had CD4 count above 200. The mean CD4 count was 99.15(SD 69.274), 
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median 87 and the minimum being 1 while the maximum was 427(only one patient), 75% were 
below 150. 
The mean baseline haemoglobin (Normal value >11.5) was 12.11mg/dl (SD 2.35089), 
minimum 5.1 and maximum 18.2%. The mean liver function test (ALT, Normal value 0 to 50) 
was 40.1504 (SD=36.55850).The mean weight was 52.0671kg(SD 9.86875) and median 51kg  
with minimum 24 and maximum 125kg. 
Majority of the patient were ambulatory 282(39.7%) and bedridden191 (26.9%) in their 
functional status. Most of the patient started ART at WHO stage III 372(52.4%) and VI 
239(33.7%), and only 96(13.5%) at WHO stage I and II. 
About 29(4.1%) already had TB at the start of ART and 167(23.6) on treatment for TB 
intensive or continuation phase. 20(2.8%) were exposed to some sort of ARV (as treatment or 
PMTCT). 
List of Baseline characteristics of the study participants are in table 5 
Table. 5– Baseline characteristics of ART patients, Bella Defence Hospital, 2009 
Baseline characteristics Frequency in number % 
CD4  
0 – 50 
51 – 100 
101 – 150  
150 – 200 
>200 
 
211 
186 
138 
115 
59 
 
29.7 
26.2 
19.4 
16.2 
8.3 
Hemoglobin 
<10mg/dl 
>=10 
 
110 
556 
 
15.5 
78.3 
Functional status 
Working 
Ambulatory 
Bedridden    
 
218 
282 
191 
 
30.7 
39.7 
26.9 
WHO stage 
Stage 1 and 2 
Stage 3 
Stage 4      
 
96 
372 
239 
 
13.5 
52.4 
33.7 
 
ARV exposure 
Yes 
No 
 
20 
689 
 
2.8 
97.0 
Past TB treatment 
Yes 
 
291 
 
41 
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Baseline characteristics Frequency in number % 
No 416 58.6 
TB at the start of ART 
Yes 
No 
 
29 
560 
 
4.1 
78.9 
TB treatment at the start 
Yes 
No 
 
167 
541 
 
23.6 
76.2 
Liver function  
<=50 
>50 
 
508 
135 
 
 
71.5 
19 
 
 
6.3. Treatment and follow up  
Majority, 317(44.6) started their treatment with regimen 1a and with 1b 222(31.3%), 127(17.9) 
with 1d and 41(5.9%) with 1c. Of these 189(26.6%) changed their regimen, but only 
116(16.4%) from one regimen type to other, the other were dose adjustment. The main reason 
for regimen change were side effects/toxicity (74, 63.8%), New TB (27, 23.3%),) and treatment 
failure (7, 6%). 
During the ART 75(10.6%) developed side effects, and 74 necessitates drug regimen change. 
The regimen associated with side effects were 32 with 1a, 22 with 1b, 15 with 1d and 6 with 1c. 
The mean time for regimen change was 6.7months (SD=7.791), median 4 months the minimum 
being 1months and maximum 40months. 30 %( 60) of regimen change took place in the first 
one months and about 70.3 % within the first six months. Regimen change also took place for 
the second time (53) and third time (9) during the follow up of the patients. 
Other important medications documented were INH, Cotrimoxazole and fluconazol as 
prophylaxis. 666(93.8%) took cotrimoxazol and 6(0.8) are allergic to CTX, only one and two 
patient took INH and Fluconazol respectively. 
It was observed that, the regular follow up schedule according to the national guideline was 
practiced for most of the patients.  
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The mean follow up time was 12.5 months (SD=12.062761), Median 8 months (minimum 0 to 
maximum 40 months). The follow up are 2months, 25% percentiles 8months 50% and 21 
months, 75%. Thirty eight (5.4) had adherence problem (fair or poor), and 172(24.2) of the 
participants adherence status is not recorded. 
List of ARV regimen and treatment related conditions are listed in table 6. 
Table 6 - ART regimen and treatment follow up outcomes, Bella Defence Hospital, 2009 
  
ARV Drugs and other treatment 
 
Frequency in number 
 
% 
Original regimen (N=708) 
1a 
1b 
1c 
1d 
 
317 
22 
41 
127 
 
44.6 
31.3 
5.9 
17.9 
Regimen change during the follow up 
Yes 
No 
 
189 
518 
 
26.6 
73 
Reason for Regimen change(N=187) 
Side effect 
Pregnancy 
New TB 
New drug available 
Drug out of stoke 
Clinical failure 
Immunologic failure 
Other 
 
74 
3 
27 
1 
4 
3 
4 
72 
 
39.6 
1.6 
14.4 
0.5 
2.1 
1.6 
2.1 
38.5 
Occurrence of side effect 
Yes 
No 
 
75 
633 
 
10.6 
89.2 
Regimen associated with the Side 
effect(N=75) 
1a(N=317) 
1b(N=222) 
1c(N=41) 
1d(N=127) 
 
 
32 
22 
6 
15 
 
 
42.7(10.1) 
29.3(9.9) 
8(14.6) 
20(11.9) 
Cotrimoxazol prophylaxis 
Yes 
No 
Allergic 
 
666 
33 
6 
 
93.8 
4.6 
0.8 
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6.4. Patterns of response to ART 
Patterns of response to ART are described in current status of the patient, the occurrences of 
important events/outcomes and change over time in repeated measurements of important patient 
laboratory and clinical values. 
6.4.1 Current status and important outcomes 
Of the 709 who had started ART in the facility 129(18%) died, 66(9.3) lost to follow up, 
178(25.2%) transferred out to other facility and 335(47%) were on follow up (on treatment). 
During the follow up there were 61(8.6%) new TB, 8(1.1%) new OIs, and 75(10.6%) recorded 
major side effects. 
In about 116(16.9%) of the participant fall in CD4 count occurred but only 47(6.6%, 11.1% if 
the denominator is those who had more than one visit/record), full fill the national CD4 failure 
criteria.(any decrease from the baseline  or decrease by more than 50% from the follow up peak 
or persistent low CD4 count below 100). Over all 169(23.8%) responses is failure either due to 
death, failure in CD4 count or clinical failure or both (Table 7). 
Table 7 –Response/outcome description of ART patients, Bella Defence Hospital, 2009 
Outcome description Frequency  % 
Current status of the patient (N=709) 
On treatment 
Lost to follow up 
Transfer out 
Dead 
Stop 
 
335 
66 
179 
129 
1 
 
47 
9.3 
25.2 
18 
0.1 
Occurrence of important outcomes 
New TB 
New OI 
Side effects 
TB treatment 
CD4 fall 
CD4 failure 
 
61 
8 
75 
198 
116 
47 
 
8.6 
1.1 
10.6 
27.9 
16.3(if the denominator are those >1record,24.4) 
6.6(if the denominator are those >1record,11.1) 
Adherence problem 
Yes 
No 
Unknown 
 
38 
492 
172 
 
5.4 
69.3 
24.2 
Outcome failure any type(death,CD4 
for clinical failure) 
Yes 
No 
 
 
169 
540 
 
 
23.8 
76.2 
 38
6.4.2. Change over time 
Main outcomes or dependent variables which were determined during the follow up are 
CD4,heamoglobin,weight,liver function tests ,functional status, adherence, side effects, 
development of OIs and TB. Quantitative variables that were measured during the follow ups 
are analyzed for their change over time using general liner model repeated measurement. 
CD4 cell count 
The mean CD4 count change observed over time were high in the first six months that is 117, 
and 27 and 63 cell/mm3 subsequently in the next two six months. The marginal mean of CD4 
count change over time is seen in Figure 4 below.  
 
 
Figure - 4. Trends of  CD4 T-cell/mm3 mean estimate in ART patients, Bella Defence 
Hospital, 2009 
Follow up months
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Figure  – 5. Trends of CD4 T-cell/mm3 mean estimate in two groups (survivor and non 
survivor) ART patients, Bella Defence Hospital, 2009 
 
The means of CD4 count were 69.21(SD=53.476), 186(SD=94.331), 212.68(SD=112.757), and 
275.75(SD=134.995) in 0, 6, 12, and 18 months of follow up respectively. The mean 
differences were significant at 0.05 level. 
Weight 
Using general linear model repeated measurement, the mean change or increases in weight were 
highest during the first six months. The figure below shows the mean change of weight through 
the follow up. 
The means of weight were 53kg (SD=12.46595), 58.3kg(SD=10.20543), 
59.6kg(SD=10.77592), 58.7kg(SD=10.69056), 58.4kg(11.14218),and 58.5kg(SD=11.07745) at 
Follow up months
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Estimated Marginal Means of CD4
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baseline,6,12,18,24 and 30 months respectively. The mean increase was 5.3kg in the first six 
month and 1.3kg, 0.9kg, 0.4kg and 0.13kg in subsequent six months measurement. The mean 
difference are significant for the first three six months at 0.05 level. 
 
 
 
Figure – 6. Trends of  Weight of patients (in Kg) mean estimate in ART patients, Bella 
Defence Hospital, 2009 
 
Haemoglobin and liver function test 
The mean haemoglobin change from the base line was high in the first two six months and 
then after decrease. The mean haemoglobin was 12.1mg/dl (SD=2.56411), 13.8mg/dl 
(SD=1.98259), 14.9mg/dl (SD=1.84543) and 14.1mg/dl (SD=2.70369) at the base line, 6, 12 
and 18 months respectively (Figure -7). 
Follow up months
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The mean Liver function test (ALT) was 44.5(SD=40.19895), 34.6(SD=20.82413) and 
30.1(SD=18.22943) at base line, six months and one year. The general linear model repeated 
measure mean curve shows a decrease in mean ALT level in the 12 months follow up. Even 
though the records are few, it shows continuing decrease in the mean ALT value in the 24 
months follow up. The following figure shows the trend (Figure 8). 
 
Figure –7. Trends of Hemoglobin mg/dl mean estimate in ART patients, Bella Defence 
Hospital, 2009 
Follow up months
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Figure –8. Trends of Liver function test (ALT) mean estimate in ART patients, Bella 
Defence Hospital, 2009 
 
Functional status 
More study subjects had functional status of ambulatory (40.8%) at the start and working 
(64.4%) at six and subsequent follow up. The proportion of those bedridden decreased from 
27.1% to 3.2% at six months. 
Table:8.Proportion of functional status during the follow up, Bella Defence Hospital, 2009 
Functional 
status  
0 
month 
3 
month 
6 
month 
9 
month 
12 
month 
18 
month 
24 
month 
30 
month 
36  
month 
Working          
Frequency 218 252 284 246 234 189 148 99 55 
% 31.5 47.7 64.4 73.2 78.8 87.1 89.7 91.7 96.5 
Ambulatory          
Frequency 282 243 143 82 53 24 14 8 1 
% 40.8 46 32.4 24.4 17.8 11.1 8.5 7.4 1.8 
Bedridden          
Frequency 191 33 14 8 10 4 3 1 1 
% 27.6 6.3 3.2 2.4 3.4 1.8 1.8 0.9 1.8 
 
Follow up Months
1260
44 
42 
40 
38 
36 
34 
32 
30 
Estimated Marginal Means of ALT
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6.5. Outcome/response failure and Survival status 
6.5.1. Description of response failure 
There were 169(23.8%) response failure (Death, CD4 failure or clinical failure).The following 
table shows the different proportion of response failure. 
Table 9. Proportion of various types of response failure, Bella Defence Hospital, 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 
12.5% 25.0% 37.5%
1 4 5 
12.5% 50.0% 62.5%
2 6 8 
25.0% 75.0% 100.0%
10 116 126
1.4% 16.6% 18.0%
35 539 574
5.0% 77.0% 82.0%
45 655 700
6.4% 93.6% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Outcome failure 
due to death
Total 
Yes
No
Outcome failure 
due to death
Total 
Outcome failure 
due to OIs
Yes 
No
Yes No
Outcome failure due to 
CD4
Total 
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Description of response failure -any 
A total of 709 HIV infected adults starting ART had been monitored from 0 to 40 months with 
mean follow up time of 12.5 months(SD=12.06276),median 8 months.169(23.8%) are outcome 
failure. Majority of the failure, 108 (63.9%) occurred during the first 3 months of this 
79(46.8%) occurs in the first month of follow up. 
The mean survival time estimate for the whole cohort by Kaplan Meir analysis was 29.264 
months (95%CI 27.890, 30.637, SE 0.701) 
 
 
Figure –9. Kaplan Meier Estimates of any outcome failure - free survival in ART Cohorts, 
Bella Defence Hospital, 2009 
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Description of outcome failure - death 
129(18.2%) died in the cohort. Majority of the death 60(46.5%) occurred in the first one month, 
and 83(64.5%) in the first three months. The mean survival time estimate for the whole cohort 
by Kaplan Meir survival analysis was 32.001(95%CI 30.762, 33.240, SE 0.632). 
 
 
 
Figure – 10. Kaplan Meier Estimates of survival in ART Cohorts, Bella Defence Hospital, 
2009 
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Description of outcome failure – CD4 failure 
47(6.6%) patient experience CD4 count failure during their follow up. The mean time estimate 
for CD4 failure for the whole cohort was 35.964 months (95%CI 34.883, 37.045,SE 0.552). 
Majority 30(64%) of the CD4 failure occurs after six months but within one year. 
 
 
 
Figure –11. Kaplan Meier Estimates of CD4 failure - free survival in ART Cohorts, Bella 
Defence Hospital, 2009 
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6.5.2. Base line characteristics of response failure and non failure – comparison between 
death and survivor/on treatment group. 
The base line values mean comparison using independent sample t-test between those survivor 
and dead are in the table below. The mean difference in base line Age, CD4 count, 
Haemoglobin, liver function test (ALT) and weight are statistically significant at the level of P-
value 0.05 
 
Table –10. Comparison of mean of baseline characteristics between survivor and non 
survivor, Bella Defence Hospital, 2009 
 
Variables Survivor 
(on treatment) 
Non survivor 
(Death) 
Mean 
Difference 
95%CI P-value 
(Sig.2 
tailed)  Mean( SD) Mean( SD) 
Age 34.43(7.483) 36.7(8.425) 2.264 0.589,3.940 0.008 
CD4 107.84(70.788) 65.33(54.934) -42.513 -54.701,-30.326 .000 
Hg 12.3389(2.16754
) 
11.0828(2.29655
) 
-1.2561 -1.7400,-0.7722 0.000 
LFT(ALT) 35.9311(28.3093
) 
45.6356(41.7558
4) 
9.70453 1.47372,17.9353
3 
0.021 
Weight 53.5048(10.6268
4) 
48.8008(8.72380
) 
-4.70400 -6.62596,-
2.78204 
0.000 
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6.7. Determinants for response to and failure of ART 
In separate Cox model for determinants of response failure (any failure) being sex male (HR 
=1.403,95%CI1.015,1.938), age greater than>50 years (HR =2.013, 95CI%1.040,3.898),Base 
line CD4 count less than 100 (HR =1.916,95%CI1.379,2.662), haemoglobin<10mg/dl (HR 
=2.276,95%CI1.606,3.234), Functional status bedridden and ambulatory (HR 
=3.814,95%CI2.446,5.947,HR =1.778 95%CI 1.126,2.809), WHO stage 4 and 3 (HR= 
4.140,95%CI 2.006,8.546,HR =2.222,95%CI 1.071,4.611), previous exposure to ARV (HR 
=2.765,95%CI 1.358,5.633), presence of TB treatment at the start of ART (HR =2.750,95%CI 
1.014,7.455),occurrence of side effects (HR=1.976,95%CI 1.306,2.990) and presence of poor or 
fair adherence problem(HR=5.078,95%CI 3.236,7.971) were associated with response failure. 
List of independent variables and association with response failure are described in table below. 
Table -11. Bivariate Analysis (Cox model) of independent variables for any outcome 
failure in ART patients, Bella Defence Hospital, 2009 
 
Variables 
 
Number 
Number of 
Event 
 
HR 
 
95%CI 
P-
value 
Sex 
Male  
Female 
 
430 
273 
 
111 
55 
 
1.403 
1 
 
1.015,1.938 
 
0.040 
Age 
20 - 29 
30 – 39 
40 – 49 
50 + 
 
217 
321 
142 
26 
 
44 
64 
49 
11 
 
1 
0.902 
1.551 
2.013 
 
 
0.614,1.325 
1.032,2.332 
1.040,3.898 
0.006 
 
0.6 
0.035 
0.038
Distance from Bella 
Adds Ababa and surrounding 
Out of Addis Ababa 
 
387 
309 
 
104 
61 
 
1 
0.944 
 
 
0.687,1.298 
 
 
0.722 
Marital status 
Never married 
Married 
Separated/Divorced/Widow/widowed 
 
137 
460 
103 
 
30 
112 
25 
 
0.945 
1 
0.919 
 
0.632,1.4515 
 
0.565,1.418 
0.910 
0.785 
 
0.702 
Occupation 
Military  
Employed/Self employed    
              Unemployed                  
 
160 
228 
207 
 
29 
64 
56 
 
0.752 
1 
0.976 
 
0.485,1.168 
 
0.682,1.398 
0.205 
0.417 
 
0.896 
Level of education 
No education/Primary 
Secondary/Tertiary  
 
305 
369 
 
71 
83 
 
1.165 
1 
 
0.848,1.601 
 
0.346 
Disclosure status 
            Yes 
             No 
 
381 
314 
 
87 
73 
 
1 
1.073 
 
 
0.786,1.466 
 
 
0.655 
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Variables 
 
Number 
Number of 
Event 
 
HR 
 
95%CI 
P-
value 
Addiction History (Tobacco, alcohol, chat...) 
        Yes 
         No 
 
167 
515 
 
42 
109 
 
1.244 
1 
 
0.871,1.776 
 
0.230 
CD4 
<100 
>=100 
 
393 
316 
 
118 
51 
 
1.923 
1 
 
1.381,2.677 
 
0.000 
CD4 
0 – 200 
>200 
 
650 
59 
 
158 
11 
 
1.185 
1 
 
0.642,2.184 
 
0.587 
Hemoglobin 
<10mg/dl 
>=10mg/dl 
 
110 
556 
 
44 
110 
 
2.276 
1 
 
1.606,3.234 
 
0.000 
Functional status 
Working 
Ambulatory 
Bedridden    
 
218 
282 
191 
 
26 
63 
78 
 
1 
1.778 
3.814 
 
 
1.126,2.809 
2.446,5.947 
0.00 
 
0.014 
0.000
WHO stage 
Stage 1 and 2 
Stage 3 
Stage 4      
 
96 
371 
239 
 
8 
73 
87 
 
1 
2.222 
4.140 
 
 
1.071,4.611 
2.006,8.546 
0.000 
 
0.032 
0.000
ARV exposure(other than PMTCT) 
Yes 
No 
 
12 
695 
 
8 
161 
 
2.765 
 
 
1.358,5.633 
 
0.005 
TB treatment during the follow up 
Yes 
No 
 
198 
509 
 
61 
108 
 
1.416 
1 
 
1.034,1.939 
 
0.030 
TB treatment at the start of ART 
Yes 
Intensive phase 
Continuation phase 
No 
 
8 
108 
51 
541 
 
4 
33 
11 
121 
 
2.750 
1.431 
0.948 
1 
 
1.014,7.455 
0.973,2.103 
0.511,1.757 
0.073 
0.047 
0.068 
0.864 
Weight at the start below mean 
<mean(52.1kg) 
>=mean(52.1kg) 
 
375 
324 
 
106 
57 
 
1.654 
1
 
1.199,2.283 
 
0.002 
Liver function (ALT) 
<= 50 
51 – 100 
>100 
 
508 
94 
41 
 
116 
30 
10 
 
1 
0.948 
1.238 
 
 
0.497,1.809 
0.605,2.533 
0.428 
 
0.871 
0.559 
Original regimen  
1a (d4t -3TC-NVP) 
1b(drt-3TC-EFV) 
1c(AZT-3TC-NVP) 
1d(AZT-3TC-EFV) 
 
314 
223 
42 
127 
 
81 
57 
5 
25 
 
1 
1.271 
1.353 
0.694 
 
 
0.811,1.990 
0.845,2.166 
0.266,1.814 
0.347 
 
0.296 
0.296 
0.457 
Occurrence of side effect 
Yes 
No 
 
75 
573 
 
29 
99 
 
1.976 
1 
 
1.306,2.990 
 
0.001 
Cotrimoxazol prophylaxis 
Yes 
No 
 
666 
39 
 
158 
11 
 
1 
1.237 
 
 
0.671,2.281 
 
 
0.496 
Adherence problem 
Yes 
 No            
 
38 
492 
 
26 
70 
 
5.078 
1 
 
3.236,7.971 
 
0.000 
 50
However in multivariate analysis using Cox model only adherence problem (HR=5.802, 95%CI 
3.562, 9.451), previous exposure to ARV (HR=4.220, 95%CI1.664, 10.702), occurrence of side 
effects during the treatment (HR=2.161, 95%CI 1.321, 3.5350) and patient functional status at 
the start being bedridden (HR=2.039, 95%CI 1.306, 4.083) are significantly associated with 
response failure. 
Table –12. Multivariate analysis for the variables–Cox model/Final model, Bella Defence Hospital, 
2009 
  B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B) 
  Lower Upper Lower Upper Lower Upper Lower Upper 
ARV exposure 1.440 .475 9.199 1 .002 4.220 1.664 10.702
Occurrence of 
Side effects .771 .251 9.427 1 .002 2.161 1.321 3.535
Func.working    12.268 2 .002     
Func.ambulator
y .040 .288 .019 1 .890 1.041 .591 1.831
Func.bedridden .837 .291 8.286 1 .004 2.309 1.306 4.083
Poor/fair 
adherence 1.758 .249 49.872 1 .000 5.802 3.562 9.451
Sex(male) .437 .233 3.519 1 .061 1.548 .981 2.443
        
 
In other hand when the functional status is out of the model haemoglobin level <10mg/dl at the 
start of ART (HR=1.703, 95%CI 1.026, 2.829) and sex being male (HR=1.653, 95%CI 1.041, 
2.624) are significantly associated with response failure. 
 
Table –12. Multivariate Cox model, functional status is out/final model, Bella Defence 
Hospital, 2009 
 
1.099 .481 5.224 1 .022 3.001 1.170 7.702
.727 .251 8.402 1 .004 2.068 1.265 3.381
.533 .259 4.233 1 .040 1.703 1.026 2.829
1.677 .252 44.155 1 .000 5.349 3.262 8.773
.503 .236 4.544 1 .033 1.653 1.041 2.624
ARV exposure
Side effects 
Hg<10mg/dl
Poor/fair adhere 
Sex(male) 
B SE Wald df Sig. Exp(B) Lower Upper
95.0% CI for Exp(B)
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6.8. Survival analysis’s according to the determinants (Adherence problem, ARV-exposure, 
side effects and functional status, sex and haemoglobin) 
Adherence – the mean survival time estimate for those who had adherence problem was 
12.757(12.550 – 21.964, SE 2.402) and median 12.  And 33.707(32.373 – 35.042, SE 0.681) for 
those who didn’t have adherence problem, Patients with adherence problem had decreased 
survival by 16months.Probablity of surviving for non adhering patients reaches 50%(40% and 
60% for male and female respectively), and 20%(40%and 18% for male and female 
respectively) in 12 and 40 months respectively. Test of equality of survival distributions for the 
different levels of adherence problem regroup. The difference in survival time is significant by 
Log Rank (mantel-Cox) test (P.value =0.000) 
 
Figure –12. Kaplan Meier Estimates of any outcome failure - free survival in the two 
(good vs. poor/fair adherence) ART Cohorts, Bella Defence Hospital, 2009 
Time to any outcome failure (in months)
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The mean survival time estimate for Pre treatment ARV-exposure 17.375 months (7.649 -
27.101, SE 4.962) and median 4months.But the mean survival time for those who don’t have 
pre –treatment exposure history was 29.514monthes (28.133, 30.896, SE 0.701).pre-treatment 
ARV exposed had reduced survival by 12months. Log Rank (mantel-Cox) test p-value=0.003 
 
 
 
Figure –13. Kaplan Meier Estimates of any outcome failure - free survival in the two 
(ARV exposed vs. non exposed) ART Cohorts, Bella Defence Hospital, 2009 
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The mean survival time for those who develop side effects was 25.750 months (21.904-
29.596,SE 1.962) and median 27 months. For those who doesn’t have side effects the mean 
survival time was 32.063 months(29.729 – 32.416,SE 0.711).The Log rank(mantle –Cox)test-
value =001.But in pair wise Log rank test for sex, it is not significant for females(P-value 
=0.513) 
 
 
Figure –14. Kaplan Meier Estimates of any outcome failure - free survival in the two (Side 
effect vs. No side effects) ART Cohorts, Bella Defence Hospital, 2009. 
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Figure –15.  Kaplan Meier Estimates of any outcome failure - free survival in the two 
(Side effects vs. No side effects) Female ART Cohorts, Bella Defence Hospital, 2009 
 
 
 
 
 
 
 
 
 
Time to any outcome failure (in months)
40.0
0
30.0
0
20.0
0
10.0
0 
0.0
0 
Cum 
Survival 
1.
0 
0.
8 
0.
6 
0.
4 
0.
2 
0.
0 
Censored 
Survival Functions
Sex = female
Side effects
No side effects
 55
The mean survival time for those who are male was 28.301 months (26.481 – 30.120,SE 0.928). 
For those who are female the mean survival time was 31.061 months(28.999 – 33.123,SE 
1.052).The Log rank(mantle –Cox)test-value =037. 
 
 
 
Figure –16. Kaplan Meier Estimates of any outcome failure - free survival in the two 
(Male vs. Female) ART Cohorts, Bella Defence Hospital, 2009 
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The mean survival time for ART patients with base line hemoglobin level <=10mg/dlwas 
25.299months (22.019, 28.580 SE 1.674), and 30.782months (29.262, 32.301SE=0.775) for 
those Hg level >10mg/dl.those with Hg<=10mg/dl had reduced survival 5.5months.the mean 
survival time for working, ambulatory and bedridden functional status were 32.968(30.824 – 
35.113,SE =1.094),30.380(28.336 – 32.424,SE=1.043) and 22.607(19.779 – 25.434,SE=1.442) 
respectively. The difference in survival time is significant (Log Rank test-value=0.000).  
 
 
Figure –17. Kaplan Meier Estimates of any outcome failure - free survival in the two 
(Hg>=10mg/dl vs. <10mg/dl) ART Cohorts, Bella Defense Hospital, 2009 
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X. Discussion 
To my knowledge this is the first study in the Ethiopian military HIV treatment facilities 
intended to see the patterns and determinants of response to and failure of ART. 
In this facility based retrospective cohort analysis of adult HIV infected patients managed under 
normal programmatic conditions in one of the Ethiopian military HIV treatment facilities, a 
statistically significant difference was observed in the baseline characteristics of those 
responded well to and failure of ART. Adherence problem, previous exposure to ARV, 
occurrence of side effects during the follow up, lower base line haemoglobin level and impaired 
functional status were independent predictors of response failure of ART.  
 The majority (60.7%) of study participants were male unlike the national figure where much of 
the ART beneficiaries and also the prevalence are high in females. This may be due to the fact 
that Bella Defence referral hospital is providing services for national defence forces of Ethiopia 
most of its member are male. 
Most of the patients start ART at low CD4 count (55% of the participant below 100), advanced 
clinical stage (33.7%and 52.4% are WHO stage III and VI) and when their function status 
(26.9% bedridden) was impaired. This is may be due to the criteria for ART initiation or most 
of the patient especially in the earlier time, presents themselves at later stage and early 
diagnosis and testing not widely practiced in the health facilities. This was also the case in the 
national reports and a cohort study done at Arba Minch Hospital (85). 
CPT, cotrimoxazole preventive therapy was widely (93.8%) practiced during the follow up; 
however INH preventive therapy was almost nil. This may be mainly because separate INH 
drug is not available, TB screening/exclusion of TB was difficult and also in some developing 
countries health care workers don’t believe IPT is beneficiary (80). 
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Patterns of Response 
The patterns of response observed in this cohort study revealed that significant (129, 18%) 
number of ART patient died. The observed high death rate is also consistent with study from 
Haiti and in the early era of HAART in developed world (80, 85). In the Tanzanian study with 
median follow up time of 10.9 months 29.7 %( 95) death occurred. The lost follow up also 
9.7%(31) for the whole cohort in the follow up time(60.This  may also be due to the high rate of 
death in earlier time/beginning of ART in Ethiopia where most of the patients are late 
presenter/presented at advanced or end stage . The lost follow rate (9.3%) in the cohort is much 
lower than the national reports and comparable to the Defence health facility reports and the 
study in Haiti (80). The transfer out rates are also high (178, 25.2%) in this cohort, it may be 
because Bella Defence Hospital is the referral hospital and patient comes from every corner for 
treatment and send back when feel better. most of the transfer out is also for those who live 
outside Addis Ababa (138, 77.5%). In recent years there were also expansions of ART services 
in NDFE where patients will be transferred out. 
Tuberculosis: the study identified a high occurrence of new TB (61, 8.6%) among the cohort, 
higher than similar study in Haiti (41, 5%) (80). It may be due to high burden of TB in 
Ethiopian general population or some other factors like the absence of INH prophylactic 
therapy in these cohort. 
In contrary to our assumption, the presence or diagnosis of TB at the start of ART (29, 4.1%) 
and the fact that most of the patients were on TB treatment (167, 23.6%) during their ART 
initiation, the multivariate Cox analysis showed non significant associations with response 
failure. However, TB treatment especially initiation phase strongly predicts response failure in 
bivariate Cox analysis. Study from Haiti also identified that there was no significant difference 
in survival between patients with and patients with out tuberculosis (80).  
 59
 
Side effects: significant number of patients develops side effects (75, 10.6%) and almost all 
(74) necessitates regimen change. The findings are also consistent with rates of side effects in 
the Haiti study (102, 11 %( 91, 10%).Recent study from developed country demonstrated that 
people of African decent are at greater risk than others for central nervous system side effects 
from efavirenz (80). Unfortunately specific types of were not documented in the follow up 
records where the study conducted and difficult to know the rates of the various types of side 
effects. 
CD4 cell response 
In about 116(16.9%) of the participant fall in the CD4 count was observed but only 47(6.6%) 
full fill the national CD4 failure criteria. The observed CD4 fall may be due to laboratory error, 
since the 95% CI for a true 100cells/mm3 is 118 to 337cells/mm3 or it is because due to 
laboratory, seasonal or diurnal variation. The effects of concomitant infection or use of 
corticosteroids might also bring about fall in CD4 count.  
Taking the whole cohort, rapid increment of CD4 count (117cell/mm3) occurs in the first six 
months and then after slow increment (27 and 63 cell/mm3) in the next two six months. Study 
from South Africa also demonstrate almost similar finding, that there were rapid increments of 
median CD4 value (25.5cell/mm3/month) in first four months and then 7.7cells/mm3/month in 
the next eight months (88). The Haitian study also revealed that the median increments at six 
months were 128cell/mm3 (80). Studies also showed that the rapid increment phase is not 
affected by the base line CD4 cell count, even those with CD4 count<50 respond at greater 
level(88). The finding in this study also  demonstrated  the same. A thesis on ART service 
quality assessment at three Defense hospitals also indicated a mean increment of CD4 count by 
128.8cells/mm3 at six months of follow up (87) 
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Weight gain 
After the start of ART an increment in mean patient weight observed. The patient had gained a 
mean of 5.3kg at six month and then 1.3 to 0.4 in the subsequent three six months. Study from 
Haiti and other three large cohorts for low resource countries also demonstrated comparable 
findings (80,89).In the Haiti study patient had gained a median of 4kg and in the later three 
studies a median of 3kg, 5kg and 4kg increment was observed at six months of ART. 
The haemoglobin values also showed significant increment in the first 12 months where as the 
liver function test declines through time. The haemoglobin increment was predictive of 
treatment success (holding the effects of AZT). The relatively high value of at the start and 
decline in the liver function test (ALT) through time may be explained by toxic effects at the 
liver by the high rates of TB and TB treatment at the start of ART. 
As a response to the treatment the functional status of the patient improved. The proportion of 
bedridden patients (27.6%) at the start of ART decreases below 4% at six months. this was 
might be due to the good response to ART and the presence of 4% at six months may be due to 
response failure group. 
Response failure and its determinants 
In this study three types of response failure namely 129(18.2%)death,47(6.6%) failure in CD4 
count and 8 (1.1%) clinical failure as defined by occurrence of AIDS defining illness, TB or 
OIs after three months of treatment. The findings were comparable to other studies in 
developing countries (80,90), how ever cohort studies from developed and non resource 
limiting set up demonstrated much lower response failure(91,92).The difference could be early 
diagnosis and treatment, good patient base line characteristics and socio-demographic factors 
and also treatment approaches  . The study revealed that majority (64.5%) of deaths occurs in 
the first three months, mostly (46.5%) in the first month. A prospective cohort study in Ethiopia 
 61
findings also revealed high mortality in early weeks of treatment (85). The high mortality in the 
first months of ART may tell the need of close and quality clinical follow at this time. 
 A statistically significant differences in the mean base line characteristics of the survivor (those 
on treatment) and non survivor (dead) were found. The differences are the mean age at the start 
was higher in the non survivor, whereas the mean CD4 count, weight, and haemoglobin were 
lower. Mean Liver function test (ALT) was higher in non survivor, which may be explained by 
relatively high proportion of TB treatment (34.1% vs 26.7%) among the non survivor that have 
toxic effects on the liver or the non survivor may have concomitant liver infection during the 
initiation of treatment or it may be due to other factors. However the survival is time dependent 
and base line factors effect changed over time and confounded by different variables, it is 
unable to label them as predictors of survival or response failure with out further analysis. 
The result from Kaplan Maier survival analysis(any failure)  revealed that the estimated 
probability of survival at 1,3,6,12,24, and 34 months of treatment was 
91.1%,87.2%,81.2%,75.2%,69.9% and 63.2% respectively. In addition the survival analysis for 
response failure due to death, the estimated proportion of surviving at 1,3,12,24 and 33 months 
after treatment were 91.4%,87.5%,82.8%,80.3%,77.9% and 75.3% respectively. The trends 
demonstrate relatively high decrease in the probability of survival in the first and third months 
of treatment. This may be related to the high burden of disease and advanced clinical stage of 
patient at the start of ART. The findings are comparable to the Haitian study that estimated 87% 
survival probability at 12 months of treatment (80) and the study from Tanzania that estimated 
80.8%,71% and 59.3% survival probability at 3,12 and 36 months after treatment 
respectively(90).The difference could be explained by the social, nutritional or other 
interventions other than ART. 
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Determinants of response failure: the analysis using bivariate Cox model reviled that sex being 
male, age at the start of ART >50years, base line CD4 cell count <100, haemoglobin <10mg/dl, 
advanced clinical stage (functional status being bedridden and WHO stage 4 and 3), previous 
exposure to ARV (other than PMTCT), occurrence of side effects during treatment, concurrent 
intensive phase TB treatment at the start of ART and poor or fair adherence increase the 
hazards for response failure. However when the variables analyzed using multivariate Cox 
model only poor or fair adherence, previous exposure to ARV(other than PMTCT),occurrence 
of side effects, haemoglobin <10mg/dl  and functional status bedridden were found to be 
statistically significant determinants of response failure. 
Haemoglobin level as important predictors of disease progression and mortality was also 
reported in the Tanzanian and other studies (90, 93). Strong association of poor adherence with 
treatment failure had been also identified in studies from both developed and African countries 
(89,94,95). The effect of adherence on the treatment outcome is obvious and previous exposure 
to ARV and its association with response failure may tell about the presence of resistance to 
ARV. Occurrence of side effects may directly affect the adherence or disrupts the 
pharmcodynamics or kinetics of ARV, or the presence of drug interaction or poor tolerance of 
the patient. But it is uncertain whether the association between anaemia and response failure is 
causal or whether anaemia is rather a marker of progressive HIV diseases. The confounding 
association between functional status being bedridden and haemoglobin<10mg/dl may give a 
clue in that anaemia would be a marker of progressive HIV disease. 
Limitation 
The followings were the limitation of the study and the interpretation and generalization of the 
findings should be taken cautiously: 
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First, due to the retrospective and observational design of this study, it was unable to control 
factors specific to patients (e.g. adverse nutritional and psychosocial issues), facilities infection 
control measures, programs and diagnostic strictness (e.g. low sensitivity and specificity of x-
ray imaging, low sensitivity of AFB).In patients with only one clinic visit we were unable to 
determine the degree of patient adherence to ART from the patient records. Even though 
assessing and documentation of patient adherence to ART was standardized it seems it is 
difficult in the real clinical practice, however, this reflects usual clinical practice and was the 
strongest predictor for both failure analysis. Lack of information on some risk factor for 
mortality and the exact cause of mortality and Issues of drug interactions were not available in 
this study. 
Second, possible selection biases of HAART strategy towards patients with more sever disease 
and also the study was conducted in the hospital setting. 
Third, mortality might be underestimated, since patient lost to follow up probably including 
individuals dying at home without being reported. Although the proportion of patients lost to 
follow up in this study (9.3%) was comparable to other African studies (90), data quality would 
be improved with better cohort retention. 
Fourth, resistance testing at baseline, and therefore it was difficult to distinguish patients with 
ART   failure because of primary drug resistance from those with ART failure of other causes, 
including poor adherence. However, primary resistance to ARV drugs is still rare in ARV naïve 
patients, reports from other African countries strengthens this (89)  
Five, although more reliable than the routine clinical follow up data records, National/WHO 
standard paper formats and registers’ data  are not as complete and may be less accurate than 
clinical trial or research data’s.    
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Despite the limitation this study suggests that data collected as part of routine care in standard 
formats can be used to identify patients at increased risk of failing their ART during their 
follow up. 
Strength 
Its Cohort nature, relatively long follow up date used and the first study in the Ethiopian 
military HIV treatment facilities that evaluates the response to ART and its determinate were 
the strong side of the study. The use of advanced statistical methods and inclusion of almost all 
patients who took ART in the facility made the study more strong. 
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XI. Conclusions 
The patterns of response to and failure for ART in Ethiopian military hospital ART clinics are 
comparable to other resource limited countries, even though mortality were much higher than 
developed world. Response failure, specially mortality was found to be high, with the majority 
of death occurs within three months of starting ART. Most of the patients started ART at 
advanced immunodeficiency stage (both clinical and CD4 count), therefore early diagnosis and 
treatment of HIV should be well addressed. Adherence problem, previous exposure to ARV, 
occurrence of side effects and impaired functional status/haemoglobin <10mg/dl are 
independent predictors of response to and failure for ART. Low base line CD4 count, TB 
treatment during ART, weight, age and sex are associated in Bivariete analysis with increased 
hazards for response failure but not significant. There is non significant difference in the 
response failure for ART in the various regimen of ART. The baseline characteristics’ of the 
patient has important associations with the response to ART. About a quarter of patients had 
response failure (169, 23.8%) and significant number (66, 9.3%) lost to follow up, even though 
it was lower than the national reported figures. Statistically non significant using multivariate 
Cox model, but important association observed was male sex had increased hazard ratio to 
response failure than female(some studies also describes this(88,91).   
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XII. Recommendation 
For health care workers in the clinical practice: 
• In order to avoid late or advanced clinical and immunodeficiency presentation at the start 
of ART, early diagnosis of HIV patients at various clinics and voluntary testing at the 
general population should be strengthened. The referral and linkage from HCT service 
providers and ART clinics should also examined. 
• In order to prevent the many deaths that occur during the first three months(especially the 
first one month)  of       antiretroviral therapy, health workers should plan for close follow 
up, identification of risk factors  and  frequent contact with patients during the early phase 
of treatment. Patients should also be informed about the need and the importance of close 
and frequent contacts to avert possible failure of ART. 
• Documenting the baseline characteristics of the patient, and clinical stage, body weight, 
hemoglobin should be viewed as important component of the routine clinical care for 
patients on antiretroviral therapy. 
• Health workers in ART clinics should be prepared to promote, assess possible factors of 
adherence problem and help their patients adhere to their medication. 
• Health care worker should also assess the adherence barriers and the compliance of their 
patient before dispensing ARV, in order to avert prior exposure to ARV and poor 
adherence. 
For programs managers and decision makers: 
• Strategies to identify, diagnose and treat HIV infected patients should be strengthened and 
the referral and linkages among the various testing centers also should be addressed. 
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• The need for improving the quality of patient management at early phase of treatment 
(health care workers capacity, diagnostic capacity for OIs and other infections). 
• To practice evidence based medicine, the health care works practice need to be integrated 
to research practices. 
• Strategies to address the barriers of adherence should also be revised and strengthened. 
• The high TB occurrence during ART may be due to absence of INH preventive treatment 
in the health facilities and this should be addressed. 
• Clinical documentation practice was encouraging and further work has to be done to 
reduce some problems and also electronic documentation should be thought. 
• Important patients follow up characteristics like BMI(studies identified it as important 
nutritional status assessment tool and predictors of failure was not be able to calculated 
since height is not recorded and it should be addressed  
For research 
• Risk factors or specific determinants of death at the early phase of treatment should be 
investigated further. 
• Factors related to side effects and sex/gender should also be investigated closely.  
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